NEUROCRINE BIOSCIENCES INC 4

Neurocrine Biosciences CLO Darin Lippoldt exercised 10,000 stock options at $81.49 and sold 10,000 NBIX common shares at an average of about $179.60 on July 9, 2026 under a Rule 10b5-1 plan.

On July 9, 2026, Neurocrine Biosciences Inc. Chief Legal Officer Darin Lippoldt exercised 10,000 non-qualified stock options with a strike price of $81.49 per share, acquiring 10,000 shares of common stock, and on the same day sold 10,000 shares of common stock at a weighted average price of $179.6014 per share pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 9, 2025. The option exercise did not involve a cash outlay in the Form 4 coding (price shown as $0 for the derivative transaction line, with the $81.49 representing the option exercise price), while the sale generated proceeds of approximately $1.8 million. After these transactions, Lippoldt’s direct ownership decreased to 54,729 shares of common stock, which, using the reported sale price as a proxy for current value, represents an equity stake worth roughly $9.8 million. The derivative security disclosed was an option originally granted on February 5, 2018, vesting in 48 equal monthly installments beginning March 5, 2018, and the reported sale was executed by a broker in multiple trades within a narrow price range of $179.50 to $179.80 per share.

Filing Facts

CIK

914475

Ticker

NBIX

Form

4

Source Type

fda

Accession

0001504783-26-000017

Alert Tier

6